HN2003000051A - Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico. - Google Patents
Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico.Info
- Publication number
- HN2003000051A HN2003000051A HN2003000051A HN2003000051A HN2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A HN 2003000051 A HN2003000051 A HN 2003000051A
- Authority
- HN
- Honduras
- Prior art keywords
- butilbencil
- piridin
- terc
- amino
- acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 4
- 239000002207 metabolite Substances 0.000 title abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A METABOLITOS DEL ACIDO (3-{[4-TERC-BUTILBENCIL)-(PIRIDIN-3-SULFONIL)AMINO}METIL] FENOXI)ACETICO. LA PRESENTE INVENCION SE REFIERE TAMBIEN A PROCEDIMIENTOS DE TRATAMIENTO DE LA OSTEOPOROSIS Y DE AYUDA A LA CURACION DE FRACTURAS OSEAS UTILIZANDO UN METABOLITO DEL ACIDO (3-{[4-TERC-BUTILBENCIL)-PIRIDIN-3SULFONIL)AMINO]METIL}FENOXI)ACETICO. ADEMAS LA PRESENTE INVENCION SE REFIERE A PROCEDIMIENTOS DE DETERMINACION DE SI SE HA ADMINISTRADO A UN PACIENTE ACIDO (3-{[4-TERC-BUTILBENCIL) - (PIRIDIN-3-SULFONIL)AMINO] METIL} FENOXI)ACETICO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35374802P | 2002-01-31 | 2002-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2003000051A true HN2003000051A (es) | 2003-09-24 |
Family
ID=27663249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2003000051A HN2003000051A (es) | 2002-01-31 | 2003-01-28 | Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6852863B2 (es) |
| EP (1) | EP1470109A1 (es) |
| JP (1) | JP2005521668A (es) |
| KR (1) | KR20040077884A (es) |
| CN (1) | CN1625549A (es) |
| AP (1) | AP2004003094A0 (es) |
| AR (1) | AR038332A1 (es) |
| BR (1) | BR0307339A (es) |
| CA (1) | CA2473984A1 (es) |
| EA (1) | EA200400724A1 (es) |
| EC (1) | ECSP045215A (es) |
| GB (1) | GB2400100B (es) |
| HN (1) | HN2003000051A (es) |
| HR (1) | HRP20040683A2 (es) |
| HU (1) | HUP0500012A2 (es) |
| IL (1) | IL162167A0 (es) |
| IS (1) | IS7281A (es) |
| MA (1) | MA27169A1 (es) |
| MX (1) | MXPA04004960A (es) |
| NO (1) | NO20043569L (es) |
| OA (1) | OA12760A (es) |
| PA (1) | PA8564601A1 (es) |
| PE (1) | PE20030978A1 (es) |
| PL (1) | PL371982A1 (es) |
| TN (1) | TNSN04138A1 (es) |
| TW (1) | TW200302080A (es) |
| UY (1) | UY27632A1 (es) |
| WO (1) | WO2003064391A1 (es) |
| ZA (1) | ZA200404067B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| TWI332937B (en) * | 2005-04-20 | 2010-11-11 | Lg Chemical Ltd | Additive for non-aqueous electrolyte and secondary battery using the same |
| EA200970067A1 (ru) * | 2006-07-28 | 2009-08-28 | Пфайзер Продактс Инк. | Агонисты ep2 |
| AU2008226947B2 (en) | 2007-03-08 | 2014-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| ES2718813T3 (es) * | 2008-03-12 | 2019-07-04 | Ube Industries | Compuesto de ácido piridilaminoacético |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| ES2477552T3 (es) | 2008-09-08 | 2014-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos |
| US8389522B2 (en) | 2008-10-28 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
| HRP20160104T1 (hr) | 2009-03-30 | 2016-03-25 | Ube Industries | Farmaceutski pripravak za liječenje ili prevenciju glaukoma |
| DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
| US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
-
2003
- 2003-01-20 KR KR10-2004-7011618A patent/KR20040077884A/ko not_active Ceased
- 2003-01-20 MX MXPA04004960A patent/MXPA04004960A/es unknown
- 2003-01-20 BR BR0307339-4A patent/BR0307339A/pt not_active IP Right Cessation
- 2003-01-20 JP JP2003564014A patent/JP2005521668A/ja active Pending
- 2003-01-20 HU HU0500012A patent/HUP0500012A2/hu unknown
- 2003-01-20 CN CNA038029952A patent/CN1625549A/zh active Pending
- 2003-01-20 CA CA002473984A patent/CA2473984A1/en not_active Abandoned
- 2003-01-20 PL PL03371982A patent/PL371982A1/xx not_active Application Discontinuation
- 2003-01-20 HR HR20040683A patent/HRP20040683A2/hr not_active Application Discontinuation
- 2003-01-20 OA OA1200400198A patent/OA12760A/en unknown
- 2003-01-20 EA EA200400724A patent/EA200400724A1/ru unknown
- 2003-01-20 WO PCT/IB2003/000121 patent/WO2003064391A1/en not_active Ceased
- 2003-01-20 IL IL16216703A patent/IL162167A0/xx unknown
- 2003-01-20 GB GB0413967A patent/GB2400100B/en not_active Expired - Fee Related
- 2003-01-20 AP APAP/P/2004/003094A patent/AP2004003094A0/en unknown
- 2003-01-20 EP EP03700072A patent/EP1470109A1/en not_active Withdrawn
- 2003-01-24 TW TW092101619A patent/TW200302080A/zh unknown
- 2003-01-28 HN HN2003000051A patent/HN2003000051A/es unknown
- 2003-01-28 PE PE2003000086A patent/PE20030978A1/es not_active Application Discontinuation
- 2003-01-29 AR ARP030100254A patent/AR038332A1/es unknown
- 2003-01-29 US US10/353,671 patent/US6852863B2/en not_active Expired - Fee Related
- 2003-01-30 UY UY27632A patent/UY27632A1/es not_active Application Discontinuation
- 2003-01-30 PA PA20038564601A patent/PA8564601A1/es unknown
-
2004
- 2004-05-21 IS IS7281A patent/IS7281A/is unknown
- 2004-05-25 ZA ZA200404067A patent/ZA200404067B/en unknown
- 2004-07-21 MA MA27796A patent/MA27169A1/fr unknown
- 2004-07-27 TN TNP2004000138A patent/TNSN04138A1/fr unknown
- 2004-07-30 EC EC2004005215A patent/ECSP045215A/es unknown
- 2004-08-26 NO NO20043569A patent/NO20043569L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2473984A1 (en) | 2003-08-07 |
| GB2400100B (en) | 2006-04-12 |
| US6852863B2 (en) | 2005-02-08 |
| TW200302080A (en) | 2003-08-01 |
| PL371982A1 (en) | 2005-07-11 |
| GB2400100A (en) | 2004-10-06 |
| ZA200404067B (en) | 2005-08-29 |
| HRP20040683A2 (en) | 2004-10-31 |
| HUP0500012A2 (hu) | 2005-04-28 |
| PA8564601A1 (es) | 2003-09-05 |
| MXPA04004960A (es) | 2005-04-08 |
| AR038332A1 (es) | 2005-01-12 |
| OA12760A (en) | 2006-07-04 |
| IS7281A (is) | 2004-05-21 |
| MA27169A1 (fr) | 2005-01-03 |
| US20030216445A1 (en) | 2003-11-20 |
| CN1625549A (zh) | 2005-06-08 |
| TNSN04138A1 (fr) | 2007-03-12 |
| KR20040077884A (ko) | 2004-09-07 |
| WO2003064391A1 (en) | 2003-08-07 |
| EP1470109A1 (en) | 2004-10-27 |
| JP2005521668A (ja) | 2005-07-21 |
| GB0413967D0 (en) | 2004-07-28 |
| EA200400724A1 (ru) | 2004-12-30 |
| IL162167A0 (en) | 2005-11-20 |
| AP2004003094A0 (en) | 2004-09-30 |
| PE20030978A1 (es) | 2003-11-19 |
| ECSP045215A (es) | 2004-09-28 |
| UY27632A1 (es) | 2003-08-29 |
| BR0307339A (pt) | 2004-12-07 |
| NO20043569D0 (no) | 2004-08-26 |
| NO20043569L (no) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2003000051A (es) | Metabolitos del acido (3-{4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico. | |
| SE0100568D0 (sv) | Compounds | |
| MXPA04000599A (es) | Derivados del acido indan acetico y su uso como agentes pharmaceuticos, intermediarios, y metodo de preparacion. | |
| GB0211649D0 (en) | Organic compounds | |
| BRPI0416628A (pt) | uso de compostos orgánicos | |
| EA200500715A1 (ru) | Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких | |
| UA86977C2 (ru) | Производные гидантоина для лечения обструктивных болезней дыхательных путей | |
| BRPI0717794B8 (pt) | composto e composição farmacêutica de ácido 3-amino-1-propanosulfônico | |
| SE0100567D0 (sv) | Compounds | |
| NZ527123A (en) | Oxazolyl-pyrazole derivatives as kinase inhibitors | |
| SE0200979D0 (sv) | New compounds | |
| MX2010010505A (es) | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). | |
| WO2007120557A3 (en) | Method and apparatus of low strengh electric field network-mediated delivery | |
| MA28153A1 (fr) | Acides nucléiques se liant spécifiquement à la ghréline biologiquement active | |
| SE0100566D0 (sv) | Compounds | |
| BRPI0411122A (pt) | pirazol[3,4-b]piridin-6-onas como inibidores gsk-3 | |
| EA200700777A1 (ru) | Содержащие октенидин таблетки для рассасывания, предназначенные для лечения воспалительных заболеваний полости рта и глотки | |
| DK1885333T3 (da) | Farmaceutisk formulering af apomorphin til bukkal indgivelse | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| WO2005030177A3 (en) | Pharmaceutical formulation with improved stability | |
| DK1525215T3 (da) | Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner | |
| EA200500764A1 (ru) | Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально | |
| SE0402507D0 (sv) | Medicinsk lösning, förfarande för framställning och användning därav | |
| DK1981906T3 (da) | Human sædfremmer af virale infektionspeptider (SEVI) og deres anvendelse | |
| SE0101692D0 (sv) | Compounds |